Display options
Cite
Smets I, Holden D, Bianchi L, et al. Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study. Mult Scler Relat Disord. 2021;57:103409doi: 10.1016/j.msard.2021.103409.
Smets, I., Holden, D., Bianchi, L., Ammoscato, F., Allen-Philbey, K., Baker, D., Turner, B., Marta, M., Giovannoni, G., Macdougall, A., Schmierer, K., Hobart, J., & Gnanapavan, S. (2021). Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study. Multiple sclerosis and related disorders, 57103409. https://doi.org/10.1016/j.msard.2021.103409
Smets, Ide, et al. "Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study." Multiple sclerosis and related disorders vol. 57 (2021): 103409. doi: https://doi.org/10.1016/j.msard.2021.103409
Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M, Giovannoni G, Macdougall A, Schmierer K, Hobart J, Gnanapavan S. Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study. Mult Scler Relat Disord. 2021 Nov 22;57:103409. doi: 10.1016/j.msard.2021.103409. Epub 2021 Nov 22. PMID: 34871856.
Copy Download .nbib Format: NLM
Share it on

Mult Scler Relat Disord. 2021 Nov 22;57:103409. doi: 10.1016/j.msard.2021.103409. Epub 2021 Nov 22.

Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study.

Multiple sclerosis and related disorders

Ide Smets, David Holden, Lucia Bianchi, Francesca Ammoscato, Kimberley Allen-Philbey, David Baker, Benjamin Turner, Monica Marta, Gavin Giovannoni, Amy Macdougall, Klaus Schmierer, Jeremy Hobart, Sharmilee Gnanapavan

Affiliations

  1. Blizard Institute, Centre for Neuroscience, Surgery & Trauma, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, 4 Newark St, Whitechapel, London E1 2AT, UK; Clinical Board Medicine (Neuroscience), Department of Neurology, Royal London Hospital, Barts Health NHS Trust, Whitechapel Road, London E1 1FR, UK.
  2. Blizard Institute, Centre for Neuroscience, Surgery & Trauma, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, 4 Newark St, Whitechapel, London E1 2AT, UK.
  3. Clinical Board Medicine (Neuroscience), Department of Neurology, Royal London Hospital, Barts Health NHS Trust, Whitechapel Road, London E1 1FR, UK.
  4. Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
  5. Faculty of Medicine and Dentistry, Institute of Translational & Stratified Medicine, Plymouth Science Park, Davy Road, Devon, Plymouth PL6 8BX, UK.
  6. Blizard Institute, Centre for Neuroscience, Surgery & Trauma, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, 4 Newark St, Whitechapel, London E1 2AT, UK; Clinical Board Medicine (Neuroscience), Department of Neurology, Royal London Hospital, Barts Health NHS Trust, Whitechapel Road, London E1 1FR, UK. Electronic address: [email protected].

PMID: 34871856 DOI: 10.1016/j.msard.2021.103409

Abstract

BACKGROUND: In multiple sclerosis (MS) neurofilament light chain (NfL) is a marker of neuronal damage secondary to inflammation and neurodegeneration. NfL levels drop after commencement of disease-modifying treatment, especially the highly active ones. However, the factors that influence this drop are unknown.

OBJECTIVE: To examine the patient and treatment-related factors that influence CSF NfL before and after starting treatment.

METHODS: Eligible patients across two centres with two CSF NfL measurements, clinical and MRI data were included as part of an observational cohort study.

RESULTS: Data were available in 61 patients, of which 40 were untreated at the first CSF sampling (T1) and treated at the second (T2; mean T1-T2: 19 months). CSF NfL reduction correlated with age (beta = 1.24 95%CI(1.07,1.43); R

CONCLUSIONS: In this observational study, we found that factors reflecting early disease stage, including a younger age, lower disability and relapsing MS were associated with treatment response in CSF NfL. Other factors were not found to be related, including lymphopaenia in highly-active treatments.

Copyright © 2021. Published by Elsevier B.V.

Keywords: Biomarkers; Multiple sclerosis; Treatment response

Publication Types